FDA must use caution with biosimilars

April 14, 2011

William P. Bro, Kidney Cancer Association At the Kidney Cancer foundation we’re constantly seeking new ways to ensure those with cancer have access to the best medical data and medicines possible. For the past 20 years, we have served as a source of support and information for individuals and their loved ones affected by kidney […]

Read More


Workplace drug plans due for ‘radical change’: experts

April 14, 2011

Tom Blackwell, National Post A growing tide of high-priced specialty medicines for arthritis, cancer and other diseases is set to put unprecedented pressure on workplace drug plans, likely forcing strict limits on what they cover, higher employee premiums and even an end to some plans altogether, experts are warning. Read more

Read More


Drugmakers could take hit under Obama budget

February 16, 2011

Obtaining approval of new drugs can take as much money as $1 billion by the time research, manufacturing, safety and clinical trials have concluded. The pharmaceutical company patents the drug as soon as it is made, usually very early in the process of drug development. The patent protects that drug from being copied by anyone […]

Read More


Drug Firms Attack U.S. Patent Plans

February 16, 2011

A U.S. government proposal to bring cheaper generic drugs to the market more quickly and help curb health-care costs has triggered criticism from the European pharmaceutical sector. Many drug makers fear that cutting the patent protection for biologic drugs to seven years from 12 years will upend their business models and curtail their ability to […]

Read More


Obama budget targets brand name medicines

February 14, 2011

Big pharmaceutical companies could face increased competition from generic drugmakers under two proposals put forth by the Obama administration on Monday despite earlier savings extracted from drugmakers as part of last year’s healthcare law. Read More

Read More


Biologics Exclusivity Cut Called for in President’s Budget: All Bark, No Bite

February 14, 2011

The Obama Administration’s fiscal 2012 budget document includes a call to reduce innovator biologics exclusivity from the 12 years just enacted as part of the health care reform law to 7 years, a number more in line with the position supported by advocates on the generic/drug/purchaser/consumer side of the debate. Read More

Read More


Next generation biologic drugs provide hope for HIV/AIDS patients

January 26, 2011

James Sykes, Director of Global Policy, The AIDS Institute The Hill Our nation’s political capital, Washington D.C. also has the notorious distinction of being the HIV and AIDS capital of the United States, with at least 3 percent of its residents infected. This rate is higher than most countries in West Africa and exceeds the […]

Read More


The High Cost of Cheaper Drugs

January 26, 2011

Marcia Boyle, President and Founder, Immune Deficiency Foundation AOL News Thirty years ago my infant son was diagnosed with a rare genetic disorder that make even common cold germs potentially life threatening. His disorder — clinically termed a primary immunodeficiency disease — started me on my career as a patient activist. Read More

Read More


Biologic Drugs: Biosimilars May Be Cheaper, But Are They Safe?

December 14, 2010

Where there’s medicine, there’s money.

Read More


European Union provides a good example of effective biosimilars pathway

December 14, 2010

Biologic drugs can treat a variety of illnesses—including cancer and certain types of arthritis—imore effectively than traditional, chemical based products.

Read More